Read More

Actinium Pharmaceuticals Reports 2 Remissions And 67% ORR In Patients With A TP53 Mutation In The Phase 1 Portion Of The Actimab-A Venetoclax Combination Trial In Patients With Relapsed Or Refractory AML At The 63rd ASH Annual Meeting

Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs today announced that data from the

ATNM